Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: A phase II study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 1, 2010, Pages 62-67

  Yang, Deok Hwan ^a   Kim, Yeo Kyeoung ^a   Sohn, Sang Kyun ^b   Chung, Joo Seop ^c   Joo, Young Don ^d   Lee, Jae Hoon ^e   Lee, Jung Lim ^f   Ahn, Jae Sook ^a   Moon, Joon Ho ^b   Shin, Ho Jin ^c   Choi, Young Jin ^c   Lee, Won Sik ^d   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a  

^a Chonnam National University   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Gachon University College of Medicine   (South Korea)

^f Daegu Fatima Hospital   (South Korea)

Author keywords

Deep vein thrombosis; Del(13); Peripheral blood stem cell collection; Thromboembolic events

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN INFARCTION; DIARRHEA; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; WEAKNESS; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 77954045641     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.007     Document Type: Article

References (27)

1. Brown R, Murray A, Pope B, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol 2004; 125:743-8. (Pubitemid 38813600)
2. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160:1224-32. (Pubitemid 28093419)
3. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100:230-7. (Pubitemid 35177452)
4. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26:351-62.
5. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28:560-4. (Pubitemid 33138157)
6. Pittini V, Teti D, Arrigo C, et al. Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF. Br J Haematol 2002; 119:275. (Pubitemid 35176533)
7. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, doubleblind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26:2171-7.
8. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-6. (Pubitemid 46630462)
9. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-9. (Pubitemid 40967171)
10. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93:124-7. (Pubitemid 351156161)
11. Singhal S, Mehta J. Multiple myeloma. Clin J Am Soc Nephrol 2006; 1:1322-30.
12. Dimopoulos MA, Kastritis E. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? Leuk Lymphoma 2006; 47:2271-2. (Pubitemid 44768416)
13. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18:2044-6. (Pubitemid 40028434)
14. Wu P, Davies FE, Horton C, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 2006; 47:2335-8. (Pubitemid 44768426)
15. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18:856-63. (Pubitemid 38500205)
16. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5:112-7. (Pubitemid 38519259)
17. UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522-40.
18. Lane SW, Gill D, Mollee PN, et al. Role of VAD in the initial treatment of multiple myeloma. Blood 2005; 106:3674, author reply 3674-5.
19. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 7(suppl 5):S207-14.
20. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21:1294-9. (Pubitemid 46831819)
21. Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32:587-92. (Pubitemid 37185094)
22. Bensinger W. Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation. Curr Treat Options Oncol 2007; 8:135-43.
23. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-7. (Pubitemid 26240110)
24. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26:979-83.
25. van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with longterm survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92:1399-406. (Pubitemid 350144158)
26. Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13:7073-9. (Pubitemid 350276890)
27. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110:827-32. (Pubitemid 47267417)